The growing importance of Lyme disease in the United States has stimulated interest in the development of a safe and efficacious vaccine. The clinical manifestations of Lyme disease include erythema migrans (a characteristic rash seen in the majority of patients), early neurologic disease (particularly meningitis in association with cranial and peripheral neuropathies), carditis, and late manifestations, which may include arthritis and less frequently neurologic symptoms [1] . Although all stages of the illness can be treated with antibiotics, Lyme disease can sometimes irreversibly damage the peripheral and central nervous system and can cause refractory arthritis with joint destruction [2] . Therefore, effective preventive measures are needed.
Work in various animal models has facilitated progress toward a human vaccine. Studies in hamsters and mice demonstrated that passively or actively acquired Borrelia burgdorferi antibodies can protect against infection [3, 4] . In particular, antibodies to outer surface protein A (OspA), a 31-kDa major surface protein of B. burgdorferi, are sufficient for protection of mice against infection [5, 6] . Moreover, immunocompetent C3H/HeJ mice actively immunized with OspA are protected from intradermal challenge with B. burgdorferi or infection transmitted by the bite of B. burgdorferi-infected ticks [7, 8] . Indeed, spirochetes were destroyed within engorged ticks recovered from OspA-immunized but not control mice, indicating a dual mode of vaccine efficacy with borreliacidal activity within the host and vector [8] . These studies suggest a possible protective role for an OspA-based vaccine in humans.
Preparations of lipidated OspA are currently being assessed as vaccine candidates in humans. A lipidated OspA vaccine that had been adsorbed with aluminum hydroxide was effective in protecting mice from Lyme disease transmitted by fieldcollected ticks on the barrier islands along the coasts of Massachusetts and Rhode Island [9] . A recent report using a similar vaccine indicates that two 10-f.tg doses of recombinant OspA, prepared as a lipoprotein, either unadsorbed or adsorbed with aluminum hydroxide, were immunogenic and safe in healthy volunteers [10] .
The purpose of this study was to assess the safety and immunogenicity of three doses of 3, 10, or 30 f.tg of a candidate OspA vaccine in patients with a previous history of Lyme disease. It is necessary to determine the safety of immunization with OspA in patients with prior Lyme disease because recent reports have addressed the potential role of the immune response to OspA in the pathogenesis of Lyme disease [11] . Moreover, it is essential to evaluate the safety of an OspA vaccine in subjects with a well-documented history of Lyme disease since it is likely that once a vaccine is available, it will be administered to subjects who knowingly or unknowingly have previously been infected with B. burgdorferi.
Materials and Methods
Patients. The study groups consisted of 30 adult subjects with clinical and laboratory evidence of previous Lyme disease. All subjects had at least one manifestation of Lyme disease, documented by a member of the Yale Lyme Disease Study Group, accompanied by an elevated IgM or IgG (or both) antibody response to B. burgdorferi (determined in our laboratory by ELISA as described) [12] . Of the 30 subjects, 14 had erythema migrans, 5 had facial palsy, 2 had meningitis, 1 had carditis, 4 had chronic neurologic symptoms, and 17 had arthritis. All subjects were > 18 years of age. No subjects had active Lyme disease at time of entry into the trial. None of the subjects had chronic Lyme disease treated with antibiotic therapy within the past 3 months; had clinically significant abnormalities in any tested hematology, blood chemistry, or urinalysis parameters; were immunocompromised or had received immunosuppressant drugs within the past 6 months; or had had a splenectomy. No subjects had a history of allergies indicating a risk for anaphylactic reactions, expected to receive immune globulin or immunizations during the study, were participating in any other investigational vaccine or drug trials, or had participated in any previous Lyme disease vaccine trials. Subjects were also excluded from the study if they were pregnant or lactating or did not have a telephone at home.
Vaccine. The vaccine preparation was manufactured by SmithKline Beecham Biologicals (Rixensart, Belgium). OspA was expressed in Escherichia coli transfected with a plasmid containing the gene for OspA from B. burgdorferi sensu stricto ZS7, isolated in Germany. It was expressed as a full-length antigen with posttranslational addition of the lipid moiety and biochemically purified to homogeneity as described [9] . The OspA protein was adsorbed to aluminum hydroxide, and for each vaccination, subjects received an intramuscular injection of 3, 10, or 30 f.Lg ofthe vaccine with 0.5 mg of aluminum hydroxide (as Al[OHh), 5 mg of 2 phenoxyethanol, 150 mM sodium chloride, 5 mM sodium phosphate, and 5 mM potassium phosphate, pH 6.8 ± 0.1, in 1 mL of water.
Study design.
This was an open-label, nonrandomized, doseranging, prospective study. All subjects were> 18 years of age and had clinical and laboratory evidence of previous Lyme disease. For initial screening purposes, a history was obtained and physical examination and laboratory testing, including complete blood count, urinalysis, and serum glucose, creatinine, alanine aminotransferase, and creatinine phosphokinase determinations, were done before vaccination. Three different doses (3, 10, and 30 f.Lg) were administered in a 0-, 1-, and 2-month schedule in a prospective, nonrandomized sequence to 5, 5, and 20 subjects, respectively. Vaccine was given intramuscularly in the nondominant deltoid. Subjects were closely observed for 30 min after injection. Local or systemic signs and symptoms and oral body temperature were recorded at the completion of the vaccination procedure. Subjects in each group were enrolled consecutively. The decision to proceed to the next highest dose was made 21 days after the last subject in each group had been given the first vaccine dose and was based on tolerability and laboratory assessment.
Assessment of safety. A diary card was given to each subject to record any local or systemic signs and symptoms on the day of vaccination (30 min after vaccination and in the evening) and in the morning of each of 3 subsequent days. The subjects were requested to report to the investigator 3 (± 1) days after all injections for follow-up. At this visit, diary cards were reviewed for the following solicited signs or symptoms: local reactions at the injection site (pain, redness, swelling, and induration) and systemic reactions (elevated oral body temperature, headache, malaise, rash, and arthralgia). Unsolicited symptoms were also obtained by the investigator. Reactions were scored as absent, mild, moderate, or severe by the subject (solicited symptoms) and the investigator (unsolicited symptoms). Fever was scored at SmithKline Beecham Biologicals as mild (37.5-38.0°C), moderate (38.l-39.0°C), or severe (>39.0°C). Redness, swelling, and induration were measured by the subject, recorded on the diary card, and scored as mild (1-30 mm), moderate (>30 mm) or severe (>30 mm and persisting for >24 h). A determination was made as to whether reactions were unrelated, probably unrelated, possibly related, or definitely related to the injection. These assessments were made at the time of each of the three injections, 3 days after injection, and 1 month after the final injection (day 84 ±7 days). At each visit, a physical examination, hematology and blood chemistry testing, and urinalysis were done.
Assessment of immunogenicity. Sera were obtained from all subjects on entry into the study and at 1 month after vaccination (day 84). ELISA using whole cell lysates of B. burgdorferi or recombinant OspA as the substrate were done on the pre-and postvaccination sera according to our previously published protocols [13] . B. burgdorferi 297 was used as the whole cell sonicate for the standard ELISA at the Yale Lyme Disease Reference Laboratory. OspA was prepared as a glutathione transferase fusion protein as described [7] . OspA and the whole cell lysate were diluted to a final strength of 1 f.Lg/mL in 0.05 M sodium carbonate, pH 9.6 [13] . Triplicate sets of 96-well microtiter plates were each coated with prepared antigen (200 f.LL) and incubated overnight at 4°C. Plates were then washed three times with 0.05% PBS-Tween (PBST). Triplicate 200 f.LLlwell samples of patient sera diluted 1:100 in PBST were applied to coated plates. IgG plates were incubated for 45 min at 37°C. Both sets were then washed three times with PBST. Goat anti-human IgG-alkaline phosphatase conjugates (Sigma, St. Louis) diluted 1:1000 in PBST were then applied, 200 f.LLlwell, and the plates were incubated for 45 min. After being washed three times with PBST, 200 f.LL of freshly prepared p-nitrophenol in glycine buffer, pH 10.5, was added to each well and they were incubated for 45 min at 37°C. First reading for IgG was taken 20 min after incubation. When 200 f.LL of undiluted IgG reached an optical density of 1000 at 405 nm, the reaction was stopped with 50 f.LL of 3 M NaOH. The optical densities of the test sera were then plotted against a known positive curve and standards of 8 normal human sera freshly prepared with each ELISA according to our published data and converted to standard units reflecting the titer (e.g., 800 U means antibodies are detectable at a serum dilution of 1:800) [13] .
Results
Patient characteristics. Twenty of the subjects were men, 10 were women, and all were white. The median age was 60 years (range, 21-79). No subjects had active Lyme disease. Subjects' histories included 11 with early-stage disease and 19 with late-stage disease, including 12 who had well-documented antecedent early-stage disease. Of the 30 subjects, 14 had erythema migrans, 5 had facial palsy, 2 had meningitis, 1 had carditis, 4 had neurologic symptoms (including peripheral neuropathy, cognitive defects, motor and sensory radiculoneuritis, chronic headaches, or fatigue), and 17 had arthritis. Subjects NOTE. EM = erythema migrans; Flu = flu-like symptoms; FP = facial palsy; Hep = hepatitis; Men = meningitis; Neuro = neurologic symptoms, including peripheral neuropathy, cognitive defects, motor and sensory radiculoneuritis, chronic headache, and fatigue; Arth = arthritis.
were consecutively assigned to each vaccine dose group. All subjects who received the 3-f..lg dose had a history oflate-stage disease, whereas about equal numbers of subjects with earlyor late-stage disease received the 10-or 30-f..lg doses. For all groups, the mean duration of Lyme disease was 10 months (range, 1-216). Before vaccination all patients had been given antibiotics: 25 subjects had received oral antibiotic therapy and 18 had received intravenous antibiotics, including several who had previously received oral therapy. The mean time from treatment to the administration of the vaccine was 22 months (range, 1-84). All subjects were seropositive by ELISA for Lyme disease during their illness (table 1) .
Safety analysis. All three doses of the vaccine were well tolerated, although mild local reactions were common (table 2). In only one instance did any symptom (redness of 8 days' duration after dose I) last beyond the 4-day follow-up period.
The majority (96%) of local reactions were rated as mild by the subject. Only 3 local reactions were rated moderate or severe. Two of these occurred in the same subject, who experienced moderate redness and severe swelling after dose 1 but had no local solicited symptoms after either dose 2 or 3. Soreness was the most frequently observed local reaction and occurred in 40%-85% of the subjects for a given dose and group. The lowest incidence of local reactions occurred with the 3-f..lg dose, with no difference noted between the groups receiving 10 and 30 ug. There was no increase in the incidence of local reactions with subsequent doses.
The incidences of individual solicited systemic symptoms are given in table 3. All reported side effects were transient. The majority (81%) of systemic symptoms were rated as mild. There were 6 moderate or severe reactions reported by 3 subjects. Two of these were moderate headache, 1 was moderate (20) 5 (25) 5 (25) 17 (85) 2 (20) 1 (5) a 17 (85) 3 (20) 2 (10) 5 (25) 9 (45) NOTE. Data are no. (%).
fever, 1 was moderate fatigue, and 2 were severe fatigue. Headache, the most frequent systemic reaction, was reported with a maximum frequency of 40% for a given dose and group. The 1 case of mild rash reported after the first vaccine dose did not reappear with subsequent doses. Arthralgia was reported by 3 subjects (2 receiving the 1O-J1g and 1 receiving the 30-J1g dose). In all instances, the transient arthralgias were migratory, involved several large joints (including the shoulders, hips, elbows, and knees), lasted 24 h, and were considered mild. One subject had previously had Lyme arthritis that responded to antibiotic therapy. The 2 subjects who received subsequent vaccine doses did not reexperience this symptom. There did not appear to be any group differences in reporting systemic reactions nor was there any increase in the incidence of reactions after each successive vaccine dose. In each group, there were a variety of unsolicited adverse experiences, 5 of which (all of mild intensity) were considered possibly related to the vaccine: neck stiffness, flushing, left arm stiffness, hematoma, and erythema. One subject withdrew from the study after dose 2 because he developed babesiosis unrelated to the vaccination procedure. A second subject withdrew from the study after dose 2 because of an elevated creatinine phosphokinase level, which was attributed to vigorous sports activity. No other subject had deviations from the normal laboratory blood and urine values that were not attributable to preexisting or concomitant conditions. No abnormal biochemistry, urinalysis, or hematology values were considered related or possibly related to vaccination.
Immunogenicity analysis. We assessed whether the subjects in the study developed OspA antibodies after vaccination. All subjects had a well-documented history of clinical manifestations of Lyme disease and were seropositive for antibodies to whole cell lysates of B. burgdorferi by ELISA during their illness; however, most of these patients (80%, 24/30) did not have antibodies to OspA before immunization, as determined by ELISA with recombinant OspA. Twenty-eight of30 subjects were positive for antibodies to B. burgdorferi by whole cell ELISA at the time of the first immunization. None of the patients with early-stage disease had detectable OspA antibodies, while 6 of the 19 with late-stage disease had low-titer antibodies to OspA (100-400 U). After immunization with OspA, the geometric mean antibody titer to OspA increased > 10-fold (table 4). The incidence oflocal and systemic adverse reactions was not related to the OspA antibody titer. This was reflected in an increase in the ELISA titers to B. burgdorferi whole cell lysates as well. Twenty-two of the subjects developed very high titers of anti-OspA antibodies (6400 or 12,800 U), and persons who received the 30-J1g dose developed higher mean antibody titers (P < .01) than subjects who were administered 3 or 10 J1g. Four of the remaining 6 subjects had antibody titers between 800 and 3200 U. One subject had a titer of 400 U and I subject who received 3-J1g doses did not respond to OspA. Two subjects who were administered the 1O-J1g dose did not complete the vaccination schedule and are not included in the data (table 4).
Discussion
We evaluated the safety and immunogenicity of a candidate OspA Lyme disease vaccine in subjects with previous seropositive Lyme disease. Intramuscular injection of the three doses of OspA vaccine (3, 10, or 30 J1g) administered in three successive vaccinations was well-tolerated in patients with diverse manifestations of early-and late-stage Lyme disease, including erythema migrans, facial palsy, meningitis, neurologic symptoms, carditis, and arthritis.
Minor local side effects, such as soreness at the site of injection, were noted but did not increase with subsequent injections. Indeed, some of these side effects are probably from the injection itself or non-OspA components of the vaccine, since in previous studies in seronegative Lyme disease patients with a placebo group, soreness occurred in groups that received either NOTE. Titers are serum dilution at which reactivity is detectable and are given as geometric mean (range).
the OspA vaccine or placebo [10] . In the current study, all adverse events after immunization were short-lived. No sustained systemic side effects were noted in any of the subjects. Three subjects had transient arthralgias that were not characteristic of Lyme disease and that did not increase or recur after subsequent doses. The majority of the subjects developed strong antibody responses to OspA after vaccination. As expected, the highest antibody titers were in subjects who received the 30-p,g dose; however, high-titer antibodies were also evident in most subjects who received 3 or 10 p,g. The titers of OspA antibodies were within the range probably necessary for protection against infection, as judged by our experience with the protective capacity ofhuman OspA antibodies transferred to mice in passive protection studies, and 26 of the 28 subjects who completed the vaccination protocol achieved these levels of antibodies [14] . On the other hand, 1 subject who received the 3-p,g dose did not develop a detectable humoral response to OspA. It is not yet known if there is a subgroup of subjects who are poor or nonresponders to OspA-the answer to that question will depend on the evaluation of large numbers of healthy persons. In addition, it is possible that prior infection with B. burgdorferi had blunted the immune response in this subject, thereby diminishing the host capability to mount a strong immune response, analogous to studies of the immunomodulatory effects of B. burgdorferi infection in humans and mice [15] .
The study shows that patients with previous Lyme disease who are seropositive for antibodies to B. burgdorferi readily tolerate vaccination with OspA without major side effects. This is in agreement with previous work testing the safety and immunogenicity of another recombinant OspA preparation in healthy adults with no known history of Lyme disease [10] . Our study indicates that prior exposure to Lyme disease is not likely to result in deleterious side effects, at least up to 3 months after the initial immunization, that would preclude vaccination. All of the subjects in this study had Lyme disease that had been successfully treated with antibiotic therapy, administered either orally or intravenously, and none of the subjects had active Lyme disease. Our data suggest that vaccination of such persons with OspA does not precipitate clinically significant side effects, including symptoms that may mimic or exacerbate Lyme disease. It remains to be determined whether vaccination of patients with active Lyme disease with OspA has an effect, either detrimental or beneficial, on the manifestations of disease. Moreover, although vaccination of subjects with OspA may be safe, this finding does not exclude the possibility that the immune response to OspA that is elicited during infection is involved in the pathogenesis of disease.
Several phase III clinical trials to test the efficacy of an OspA-based Lyme disease vaccine are underway. The current study shows that it is safe to vaccinate subjects who have a history of seropositive Lyme disease. Moreover, these persons are likely to develop high titers of OspA antibodies after immunization. Therefore, screening of patients for evidence of previous Lyme disease before vaccination is an unnecessary exclusion.
